The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).
Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma
High Grade B-cell Lymphoma: Not Otherwise Specified (NOS)
Primary mediastinal B-cell lymphoma (PMBL)
Patients with newly diagnosed, previously untreated B-NHL.
Known congenital or acquired immune deficiency.
Prior solid organ transplantation.
Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher.
New York Medical College
Lead sponsor
Roswell Park Cancer Institute
Collaborator